HANNAH CUMMINS: Open Payments
NPI 1285301408 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,658 in 102 payments from 18 companies in 2025. Trend: 2023 $1,106 · 2024 $1,958 · 2025 $1,658
Food & beverage: $1,658
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $345 |
| AstraZeneca Pharmaceuticals LP | 17 | $313 |
| PFIZER INC. | 17 | $243 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $170 |
| Novo Nordisk Inc | 7 | $151 |
| Otsuka America Pharmaceutical, Inc. | 5 | $88 |
| Astellas Pharma US Inc | 2 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $41 |
| Edwards Lifesciences Corporation | 2 | $40 |
| Amgen Inc. | 2 | $35 |
Products named: VRAYLAR, CAPLYTA, FARXIGA, NURTEC ODT, BREZTRI, REXULTI, PREVNAR 20, Ozempic.
Industry payments across IN — which companies pay providers there.
